Results 21 to 30 of about 18,995 (290)

Simulating androgen receptor selection in designer yeast

Synthetic and Systems Biotechnology, 2022
Androgen receptor (AR) mutation is closely associated with prostate cancer (PCa) and is one of the mechanisms of resistance to PCa therapies such as AR antagonists. Although sequencing technologies like next-generation sequencing (NGS) contributes to the
Haoran Zhang, Lu Zhang, Yipeng Xu, Shaoyong Chen, Zhenyi Ma, Mingdong Yao, Fangyin Li, Bo Li, Yingjin Yuan   +8 more
doaj   +1 more source

In silico prediction of nuclear receptor binding to polychlorinated dibenzofurans and its implication on endocrine disruption in humans and wildlife

Current Research in Toxicology, 2021
Polychlorinated dibenzofurans (PCDFs) are known to cause endocrine disruption in humans and wildlife but the mechanisms underlying this disruption have not been adequately investigated.
Lukman K. Akinola, Adamu Uzairu, Gideon A. Shallangwa, Stephen E. Abechi   +3 more
doaj   +1 more source

Therapeutic potential of TRPM8 antagonists in prostate cancer

Scientific Reports, 2021
Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear.
Marzia Di Donato, Carmine Ostacolo, Pia Giovannelli, Veronica Di Sarno, Isabel M. Gomez Monterrey, Pietro Campiglia, Antimo Migliaccio, Alessia Bertamino, Gabriella Castoria   +8 more
doaj   +1 more source

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis

Infectious Agents and Cancer, 2021
Background Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity.
Mateus Bringel Oliveira Duarte, Frederico Leal, Juliana Luz Passos Argenton, José Barreto Campello Carvalheira   +3 more
doaj   +1 more source

Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer

Cell Reports, 2023
Summary: In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling.
Xiao Li, Fei Li, Fei Ye, Haotian Guo, Wentao Chen, Jia Jin, Yiran Wang, Pengfei Dai, Huili Shi, Hongru Tao, Wenzhen Dang, Yiluan Ding, Mingchen Wang, Hualiang Jiang, Kaixian Chen, Naixia Zhang, Dong Gao, Yuanyuan Zhang, Cheng Luo   +18 more
doaj   +1 more source

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19

iScience, 2021
Summary: Epidemiological data showing increased severity and mortality of COVID-19 in men suggests a potential role for androgen in SARS-CoV-2 infection.
Qu Deng, Reyaz ur Rasool, Ronnie M. Russell, Ramakrishnan Natesan, Irfan A. Asangani   +4 more
doaj   +1 more source

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Prostate International, 2021
Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance
Emre Yekedüz, Güngör Utkan, Ravindran Kanesvaran, Yüksel Ürün   +3 more
doaj   +1 more source

Conformational dynamics of androgen receptors bound to agonists and antagonists [PDF]

Scientific Reports, 2021
AbstractThe androgen receptor (AR) is critical in the progression of prostate cancer (PCa). Small molecule antagonists that bind to the ligand binding domain (LBD) of the AR have been successful in treating PCa. However, the structural basis by which the AR antagonists manifest their therapeutic efficacy remains unclear, due to the lack of detailed ...
Gim, Hyo Jin, Park, Jiyong, Jung, Michael E, Houk, KN   +3 more
openaire   +5 more sources

High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor

Cells, 2020
Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease ...
Hadjer Dellal, Abdelhay Boulahtouf, Elina Alaterre, Alice Cuenant, Marina Grimaldi, William Bourguet, Céline Gongora, Patrick Balaguer, Philippe Pourquier   +8 more
doaj   +1 more source

Synthesis, bioactivity, and molecular docking of novel arylpiperazine derivatives as potential AR antagonists

Frontiers in Chemistry, 2022
Prostate cancer is one of the malignant tumors and the second most common malignant tumor in men. Clinically used androgen receptor (AR)–targeted drugs can antagonize androgen and inhibit tumor growth, but these drugs can cause serious resistance ...
Yueheng Qi, Yueheng Qi, Hong Chen, Shijin Chen, Jianliang Shen, Jingguo Li   +5 more
doaj   +1 more source